生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Cerecin strengthens position in neurometabolism with addition to pipeline
2023-09-19
·
交易
·
BioSpace
引进/卖出
Cerecin
completes in-licensing of an investigational radiolabelled tracer 18FBHB, CER-022, for development and use in positron emission tomography (PET) studies of ketone body metabolism Company expands ketogenic platform following pilot data of
CER-0001
in
migraine
and
infantile spasms
. CER-022 is a novel diagnostic asset with potential applications in neurology and other therapeutic indications DENVER, Colo. and SINGAPORE, Sept. 19, 2023 /PRNewswire/ --
Cerecin Inc.
, a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced the in-license of CER-022 from the
University of Alberta
. The in-license is part of
Cerecin
's pipeline expansion and further strengthens its position as a leader in neurometabolism, addressing metabolic targets and bioenergetics in disease. CER-022 could have broad applications in the study of ketone body metabolism and will complement
Cerecin
's ongoing studies of ketosis in
migraine
,
Alzheimer's disease
and
infantile spasms epilepsy
. CER-022 is an 18Fluorinated beta-hydroxybutyrate ([18F]FBHB) for investigational use in positron emission tomography (PET) studies of ketone body metabolism. PET is an imaging technique using radiolabelled isotopes to measure metabolic activity in cells. CER-022 was developed by Dr. Frank Wuest, Professor of
Oncology
at the
University of Alberta
, and colleagues. This month, the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for the U.S. Patent Application No. 16/992,940, title: Fluorinated beta-hydroxybutyric acids for PET imaging, licensed to
Cerecin
by the
University of Alberta
. 18F radiolabeled
2-deoxyglucose (18FDG)
is used in numerous applications relating to the brain, heart and in
cancer
diagnosis. 18FDG PET has been a transformative diagnostic enabling a better understating of tissue metabolism and the early detection and treatment of diseases, particularly
cancers
and cardiac function. Similarly, it is hoped that CER-022 will be an important diagnostic tool with broad applications, being of significant value to the Company in future studies of its lead investigational drug compound, CER-0001 (tricaprilin). Commenting on the in-license, Dr Samuel Henderson, Chief Scientific Officer,
Cerecin
, said, "We are pleased to have in-licensed this technology from the
University of Alberta
. Radiolabeled glucose has proven to be a valuable tool for the study of many diseases, and with the growing interest in ketone body metabolism, a tool to study ketosis may have similar broad uses. Studies using CER-022 may increase our knowledge of the role of ketosis in a variety of applications." Dr. Frank Wuest, Professor at the
University of Alberta
said, "Our partnership with
Cerecin
will advance the study of our molecular imaging technologies and evaluate if CER-022 will be a useful tool for studying ketone body metabolism using PET. Disorders exhibiting altered energy substrate utilization, such as
Alzheimer's disease
,
epilepsy
,
diabetes
, and
cancer
may be of interest for PET imaging studies using CER-022." About
Cerecin
Cerecin
is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of
central nervous system diseases
.
Cerecin
's lead compound,
CER-0001
, is being developed for
migraine
,
Alzheimer's disease
and
epilepsy
.
Cerecin
's programs leverage its extensive experience in neurology and global drug development.
Cerecin
is supported by two multinational partners, Nestlé S.A. (NSRGY), and
Wilmar International Limited
(F34.SI), as well as a syndicate of leading institutional investors. By bringing together the deep expertise of its leadership team and highly innovative programs,
Cerecin
is becoming a global leader in bioenergetics and neurometabolism. Forward looking statements This press release contains "forward-looking statements" under applicable securities laws that are based on the current expectations and beliefs of
Cerecin
. Such statements may be accompanied by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "possible," "will" and other words and terms of similar meaning. All statements, except for statements of historical fact, are statements that could be deemed forward-looking statements, including but not limited to: (i) sources and availability of third party financing and investments and the projected financial performance of the Company; (ii) the expected development of the Company's business, projects, drug development programs and joint ventures; (iii) execution of the Company's vision and growth strategy, including with respect to future growth; and (iv) new developments with respect to the Company's projects that are currently underway, in development or otherwise under consideration. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Forward-looking statements are not guaranties of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from projections of future performance or any result that may be expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of
Cerecin
believes are reasonable assumptions, there can be no assurance or guarantee that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Cerecin
undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. For more information visit . For further information, please contact: pr@cerecin.com © 2023
Cerecin
AC-23-973 View original content to download multimedia: SOURCE
Cerecin
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Cerecin, Inc.
University of Alberta
Wilmar International Ltd.
适应症
偏头痛
婴儿痉挛
阿尔茨海默症
[+4]
靶点
-
药物
三辛酸甘油酯
2-脱氧-D-葡萄糖
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
全球生物医药交易报告(2024第3季度)
智慧芽生物医药
抗体类药物FTO报告撰写操作手册
智慧芽生物医药
罗氏双特异性抗体药物Emicizumab专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务